鹰瞳科技-B2023年中期报告

Beijing Airdoc Technology Co., Ltd. (A joint stock company incorporated in the People’s Republic of China with limited liability)Stock Code2251 CONTENTS Corporate Information2Financial Summary5Management Discussion and Analysis6Other Information33Independent Review Report54Interim Condensed Consolidated Statement ofProfit or Loss56Interim Condensed Consolidated Statement ofComprehensive Income57Interim Condensed Consolidated Statement ofFinancial Position58Interim Condensed Consolidated Statement ofChanges in Equity60Interim Condensed Consolidated Statement ofCash Flows61Notes to Interim Condensed ConsolidatedFinancial Information64Definitions and Glossary of Technical Terms94 CORPORATE INFORMATION BOARD OF DIRECTORSExecutive Directors 20231 1320233 30 Mr. ZHANG Dalei ()(Chairman and chief executive officer)Mr. GAO Fei ()(ceased on January 13, 2023)Dr. CHEN Yuzhong ()Mr. CHEN Hailong ()Ms. WANG Lin ()(effective from March 30, 2023) Non-executive Directors 20231 1320235 1920233302023727 Ms. WANG Mi ()(ceased on January 13, 2023)Mr. CHEN Xin ()(effective from May 19, 2023)Ms. ZHU Tingyao ()(effective from March 30, 2023and ceased on July 27, 2023) Independent Non-executive Directors Mr. NG Kong Ping Albert ()Dr. WU Yangfeng ()Dr. HUANG Yanlin () SUPERVISORS Mr. WEI Yubo ()Ms. BAI Huihui ()Dr. LUO Ting () AUDIT COMMITTEE Mr. NG Kong Ping Albert ()(Chairman)Dr. HUANG Yanlin ()Dr. WU Yangfeng () REMUNERATION AND APPRAISALCOMMITTEE 20231 1320233 30 Dr. HUANG Yanlin ()(Chairman)Mr. GAO Fei ()(ceased on January 13, 2023)Mr. NG Kong Ping Albert ()Ms. WANG Lin ()(effective from March 30, 2023) NOMINATION COMMITTEE Mr. ZHANG Dalei ()(Chairman)Dr. HUANG Yanlin ()Dr. WU Yangfeng () STRATEGY COMMITTEEMr. ZHANG Dalei ()(Chairman)Mr. NG Kong Ping Albert ()Dr. WU Yangfeng () AUTHORIZED REPRESENTATIVESMr. ZHANG Dalei ()Ms. SO Lai Shan () JOINT COMPANY SECRETARIES Ms. YANG Wenting ()Ms. SO Lai Shan ()(ACG (CS, CGP) HKACG (CS, CGP)) HEAD OFFICE, REGISTERED OFFICEAND PRINCIPAL PLACE OF BUSINESSIN THE PRC 22421 Room 21, 4th Floor, Building 2, A2 YardWest Third Ring North RoadHaidian DistrictBeijingPRC PRINCIPAL PLACE OF BUSINESS INHONG KONG 33191901 Room 1901, 19/F, Lee Garden One33 Hysan AvenueCauseway BayHong Kong H H SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong CORPORATE INFORMATION HONG KONG LEGAL ADVISER 1526 Kirkland & Ellis26/F, Gloucester TowerThe Landmark15 Queen’s Road CentralHong Kong PRC LEGAL ADVISER 2022–31 Zhong Lun Law Firm22–31/F, South Tower of CP Center20 Jin He East AvenueChaoyang DistrictBeijingPRC AUDITOR 97927 Ernst & Young Certified Public AccountantsRegistered Public Interest Entity Auditor27/F, One Taikoo Place979 King’s RoadQuarry BayHong Kong 2251 STOCK CODE2251 www.airdoc.com COMPANY WEBSITEwww.airdoc.com FINANCIAL SUMMARY A summary of the results and of the assets and liabilities ofthe Group for the Reporting Period together with thecomparative figures for the corresponding previous period isset out as follows: MANAGEMENT DISCUSSION AND ANALYSIS BUSINESS OVERVIEW SaMD We are an AI-based medical device company with anadvanced platform of AI-empowered retina-based deeplearning algorithms. We are one of the first to provideAI-empowered retina-based early detection, diagnosis andhealth risk assessment solutions in China. With the feature ofintegrated software and hardware solutions, we provide ourAI-based SaMDs, health risk assessment solutions andh a r d w a r e d e v i c e s t o a w i d e r a n g e o f h e a l t h c a r eenvironments, enabling us to commercialize and sell notonly to clinical departments in hospitals, but also to othertypes of medical institutions, various consumer healthcareenvironments and eye health management settings. 2023202263037.4120.6%20236 3082.52023630(i)12.6137.3%29.8(ii)17.226.0%21.7(iii)7.6307%31.02023SaMD2.9681.2% In the first half of 2023, upholding the mission of “Accessibleand Affordable to Everyone”, we had been committed todiligently advancing our business expansion. With ourcontinued efforts to boost sales, our revenue increased by120.6% from RMB37.4 million for the six months endedJune 30, 2022 to RMB82.5 million for the six months endedJune 30, 2023. This growth was driven by the improvedperformance of our three main business pillars, namely,Airdoc Medical (), Airdoc Health () andAirdoc Eye Health (). For the period ended June30, 2023, each of our business pillars saw a year-over-yearrevenue growth: (i) revenue from Airdoc Medical increasedby 137.3% from RMB12.6 million to RMB29.8 million, (ii)revenue from Airdoc Health increased by 26.0% fromRMB17.2 million to RMB21.7 million, and (iii) revenue fromAirdoc Eye Health increased by 307% from RMB7.6 millionto RMB31.0 million, which is primarily attributable to thecontinual expansion of our main business into hospital andprimary healthcare institutions, as well as our persistentefforts in promoting